Month: November 2021

Nov 09 2021

Uncategorized

Antipsychotics and New-Onset Obsessive-Compulsive Disorder in Schizophrenia

by Clinical Editor

No Comments

Comorbidity or medication adverse effect? Researchers performed a nested case-control study of new-onset obsessive-compulsive disorder following antipsychotic use in schizophrenia.

Nov 09 2021

Uncategorized

Schizophrenia drug landscape: a stagnant field on the cusp of change?

by Clinical Editor

No Comments

Several pipeline therapies could shake up the schizophrenia field, but their road through development is unlikely to be an easy path. Most new drugs in schizophrenia have relied on similar...

Nov 09 2021

Uncategorized

Schizophrenia burden totaled more than $340 billion in 2019

by Clinical Editor

No Comments

Schizophrenia’s approximate societal burden was $341.5 billion in the U.S. in 2019, according to study results presented at Psych Congress.Adjusted for inflation, this represented a 99.8% increase in …

Nov 09 2021

Uncategorized

Paliperidone palmitate may reduce schizophrenia treatment failure in Black patients

by Clinical Editor

No Comments

Paliperidone palmitate appeared to benefit Black patients with recent-onset schizophrenia or schizophreniform disorder, according to study results presented at NEI Congress. “In this poster, we presen …

Nov 08 2021

Uncategorized

Pulmonary empyema in a patient with schizophrenia and poor dentition

by Clinical Editor

No Comments

A 55-year-old man with a medical history of schizophrenia and a seizure disorder presented to our hospital with subacute onset of cough, weight loss and confusion. When we examined him,...

Nov 08 2021

Uncategorized

Antipsychotics and New-Onset Obsessive-Compulsive Disorder in Schizophrenia

by Clinical Editor

No Comments

Comorbidity or medication adverse effect? Researchers performed a nested case-control study of new-onset obsessive-compulsive disorder following antipsychotic use in schizophrenia.

Nov 08 2021

Uncategorized

Schizophrenia drug landscape: a stagnant field on the cusp of change?

by Clinical Editor

No Comments

Several pipeline therapies could shake up the schizophrenia field, but their road through development is unlikely to be an easy path. Most new drugs in schizophrenia have relied on similar...

Nov 08 2021

Uncategorized

Is Earlier Use of Long-Acting Injectable Drugs for Schizophrenia Better?

by Clinical Editor

No Comments

For Medicaid beneficiaries with schizophrenia, early initiation of long-acting injectable antipsychotics (LAIs) was associated with fewer inpatient stays and emergency room (ER) visits compared with …

Nov 08 2021

Uncategorized

Schizophrenia burden totaled more than $340 billion in 2019

by Clinical Editor

No Comments

Schizophrenia’s approximate societal burden was $341.5 billion in the U.S. in 2019, according to study results presented at Psych Congress.Adjusted for inflation, this represented a 99.8% increase in …

Nov 07 2021

Uncategorized

Antipsychotics and New-Onset Obsessive-Compulsive Disorder in Schizophrenia

by Clinical Editor

No Comments

Comorbidity or medication adverse effect? Researchers performed a nested case-control study of new-onset obsessive-compulsive disorder following antipsychotic use in schizophrenia.